
The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Latest episodes

Sep 19, 2024 • 19min
Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials
Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.
In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.

Aug 29, 2024 • 24min
Discussing AxSpA: Incidence of uveitis following bimekizumab treatment
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.

Aug 22, 2024 • 44min
Author Interview: Professor Laura Andreoli, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.

Aug 15, 2024 • 16min
Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib
Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.
In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.

Aug 12, 2024 • 31min
Discussing PsA: Secukinumab & The Effect of Sex on the Long-Term Persistence of Targeted Therapies
Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, namely the effect of sex on the long-term persistence of targeted therapies, as well as the impact of secukinumab on synovitis and enthesitis.

Aug 12, 2024 • 22min
Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status
Join Professors Hideto Kameda and Xenofon Baraliakos for insights on upadacitinib in nr-axSpA and certolizumab pegol treatment. Topics include results from a phase 3 trial, analysis of upadacitinib treatment, longer-term safety analysis, clinical outcomes of certolizumab pegol, and response rates based on MRI and CRP status in nr-axSpA patients.

Aug 12, 2024 • 33min
Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.

Aug 12, 2024 • 25min
Discussing AxSpA: Long-Term Outcomes of Secukinumab & JAKis in Clinical Practice
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to discuss another publication, which presents JAKi treatment recommendations for IMIDs from a two-round modified RAM study with 21 subject matter experts.

Aug 12, 2024 • 26min
Discussing PsA: Guselkumab and analysis of genetic markers
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and their response to biologics in inflammatory diseases.

Aug 12, 2024 • 29min
Discussing PsA: 2023 EULAR recommendations and improvements in PROs with deucravacitinib
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.